Navigation Links
Penn biochemist receives NIH New Innovator's Award
Date:10/5/2007

PHILADELPHIA - James Shorter, PhD, Assistant Professor of Biochemistry and Biophysics at the University of Pennsylvania School of Medicine, has been named an inaugural recipient of the 2007 NIH Director's New Innovator Award. This highly prestigious award totals $1.5 million in direct costs over five years to each of 29 investigators, many of whom are in the early stages of their careers. More than 2,100 applications were received for this extremely competitive program.

As a key component of the National Institutes of Health (NIH) Roadmap for Medical Research, the New Innovator Award program supports exceptionally creative early-career scientists who take highly innovative approaches to major challenges in biomedical research. Shorter will develop biochemical methods to combat diseases caused by nerve degeneration, such as Parkinsons, Alzheimers, and Huntingtons.

Novel ideas and new investigators are essential ingredients for scientific progress, and the creative scientists we recognize with NIH Directors Pioneer Awards and NIH Directors New Innovator Awards are well-positioned to make significantand potentially transformativediscoveries in a variety of areas, said NIH Director Elias A. Zerhouni, MD.

This award is an honor, and a relief, in a way, to now be able to focus on my research in a significant way, says Shorter. Shorters lab seeks to understand how cells prevent, reverse, or even promote the formation of amyloid and prion fibers, extremely stable protein aggregates implicated in many neurodegenerative diseases. He aims to test his ideas using a panel of proteins that are implicated in human disease to search for potential cures for these disorders.

When amyloid fibers grow and divide they can be infectious, and are then termed prions. Prion and amyloid formation are associated with some of the most devastating neurodegenerative diseases confronting humans, including Alzheimer's disease, Parkinson's disease, and variant Creutzfeldt-Jacob disease.

Cells have evolved a sophisticated machinery to alleviate amyloid and prion aggregates, but these biological safeguards can be breached, especially as organisms age, and the consequences are often fatal. Working in a yeast model, Shorter and colleagues employ biochemistry and genetics to understand how the interactions between amyloid proteins and other proteins can be manipulated to avoid pathogenic outcomes and promote beneficial outcomes.

Shorter received his PhD from the Imperial Cancer Research Fund at University College London in 2000 and moved to Penn from the Whitehead Institute in Boston in April 2007.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related biology news :

1. Biochemists report discovery of structure of major piece of telomerase; implications for cancer
2. UCR biochemist goes to Washington with high-protein corn
3. Precision biochemistry tracks DNA damage in fish
4. DuPonts first biologically derived polymer receives global recognition
5. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
6. Research on antibiotics receives historical recognition
7. Anthrax test, developed by army and CDC, receives FDA approval
8. Research team receives $7.5 million to study cassava
9. NJIT Presidential Award winner takes stem cell research another step
10. TGen awarded $7.1 million to accelerate brain disease research
11. Virtual microscopy project wins educational technology award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
(Date:11/17/2016)... 17, 2016  AIC announces that it has just released a new white paper ... high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or HPC ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... Research and Markets has announced the addition of Jain PharmaBiotech,s ... their offering. ... This report describes different types ... proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery ... Currently the most important applications of biomarkers are in drug ...
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Germany ... AxioMed disc in Cologne and Karlsruhe to discuss the benefits of a viscoelastic ...
(Date:12/5/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... chronic diseases, announced that Catherine Bovenizer , ... Officer (CFO), effective today. Ms. Bovenizer ... in financial management for a variety of public ... recently, Ms. Bovenizer was the Vice President of ...
(Date:12/5/2016)... 5, 2016 NxGen MDx announced today that it brought its ... house, we,ve been able to improve customer service through shortened turnaround times ... Alan Mack , CEO of NxGen MDx. ... , A decrease in turnaround ... to more job opportunities at the Grand Rapid headquarters. The ...
Breaking Biology Technology: